Pro sports’ COVID protocols led to real-world data impacts for pharma

After years of pioneering new methods for using data and technology to improve patient health outcomes, IQVIA’s Christina Mack is on the cusp of a research revolution.

By Karissa Waddick • Jan. 16, 2023

How biotechs can weather the market storm

Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

By Meagan Parrish • Jan. 13, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

A new mission in menopause — extending the lives of women

Why Evernow CEO Alicia Jackson thinks menopause is the perfect inroad to helping women live longer lives.

By Meagan Parrish • Jan. 5, 2023

Nonprofits are bridging R&D’s valley of death

How charitable firms such as Advancium are helping to right the market wrongs of drug development.

By Kelly Bilodeau • Jan. 4, 2023

The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

A preview of the top trends on the minds of industry and market leaders for the new year.

By Taren Grom • Jan. 3, 2023

To drive trial diversity, one company is bringing them to the patient

For Lightship, increasing patient access to clinical trials is about meeting them where they are — literally.

By Karissa Waddick • Dec. 21, 2022

With mpox cases mysteriously dwindling, scientists search for answers

Was it a public health victory? Or did mpox ‘burn itself out?’ An epidemiologist weighs in.

By Kelly Bilodeau • Dec. 19, 2022

Woman of the Week: Exelixis’ Dr. Vicki Goodman

With several blockbuster products under her belt, veteran oncologist and drug developer Dr. Vicki Goodman is looking to further evolve Exelixis’ pipeline to address hard-to-treat cancers.

By Taren Grom • Dec. 14, 2022

At the heart of hematology breakthroughs, a community of researchers and patients comes together

As new and advanced therapies are revealed at the annual meeting of the American Society of Hematology this week, the patients are always at the center.

By Michael Gibney • Dec. 13, 2022

The pharma giants making the biggest strides with global drug access

A recent report ranks the top 20 pharma companies by how well they’re boosting a critical component of health equity.

By Kelly Bilodeau • Dec. 12, 2022

The 2023 PharmaVoice Year in Preview

Here’s a look at how industry leaders are navigating the key issues of 2023.

Dec. 12, 2022

Takeda’s global quest for health equity

Takeda’s Center for Health Equity and Patient Affairs is built to address health inequality around the world and aims to raise the bar for the pharma industry.

By Taren Grom • Dec. 8, 2022

Non-toxic and addiction free: The promise of a new pain med

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

By Taren Grom • Dec. 1, 2022

10 of our most popular articles in 2022

Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

By Meagan Parrish • Nov. 30, 2022

Woman of the Week: Myriad Genetics’ Nicole Lambert

Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

By Taren Grom • Nov. 23, 2022

A ‘bold vision’ to prevent diabetes

Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

By Alexandra Pecci • Nov. 15, 2022

The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

By Taren Grom • Nov. 11, 2022

While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

By Michael Gibney • Nov. 8, 2022

The other ‘D’ in DE&I

How companies can work to include people with disabilities into broader equity aims.

By Taren Grom • Nov. 4, 2022

Woman of the Week: City of Hope’s Gulden Mesara

Charged with bridging the 100-year-old research center to its future mission of holistic patient cancer care, Mesara is bringing decades of experience in communications and culture creation.

By Taren Grom • Nov. 2, 2022

While DCTs get all the hype, some industry insiders say the future is a digital hybrid

Leaders at Veeva believe the wording around decentralized trials has been exaggerated, and that a bigger-picture outlook is important as the pandemic winds down.

By Michael Gibney • Nov. 1, 2022

Tips for tackling trial recruitment and retention woes in oncology

How new tools are helping companies find and keep cancer patients in clinical studies.

By Kelly Bilodeau • Oct. 31, 2022

How does the Inflation Reduction Act affect healthcare?

The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.

Oct. 31, 2022

Backed by celebrity interest, Novo is finding new success in weight loss — while staying true to its roots

The company's head of U.S. and Canadian operations explains how it’s evolving its game plan after 100 years in the insulin space.

By Meagan Parrish • Oct. 25, 2022

Checking the box on digital engagement isn’t enough

In a recent study, 50% of healthcare consumers reported that a bad digital experience can ruin the patient journey, while 39% felt that a good digital interaction had a positive influence.

Oct. 24, 2022